Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

32.54
-0.5400-1.63%
Volume:1.12M
Turnover:36.58M
Market Cap:3.14B
PE:-5.48
High:33.41
Open:32.80
Low:32.31
Close:33.08
52wk High:50.00
52wk Low:25.81
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.94
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.9427
EPS(LYR):-6.2867
ROE:-313.43%
ROA:-24.92%
PB:342.76
PE(LYR):-5.18

Loading ...

Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets

Simply Wall St.
·
Nov 09

Stock Track | Ultragenyx Pharmaceutical Plummets 5.10% as Citigroup Cuts Target Price

Stock Track
·
Nov 06

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Bank of America Securities

TIPRANKS
·
Nov 06

Ultragenyx Pharmaceutical Inc : Citigroup Cuts Target Price to $103 From $110

THOMSON REUTERS
·
Nov 06

Ultragenyx Pharma Is Maintained at Buy by Truist Securities

Dow Jones
·
Nov 06

Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth

TIPRANKS
·
Nov 05

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $72 From $77, Maintains Outperform Rating

MT Newswires Live
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plummets 11.89% Pre-market on Weak Q3 Results and Royalty Sale

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plummets 11.89% Pre-market on Royalty Sale and Weak Q3 Results

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plunges 11.83% Pre-market Following Royalty Sale and Disappointing Q3 Results

Stock Track
·
Nov 05

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Nov 05

Ultragenyx Pharmaceutical Q3 Net Loss Widens, Revenue Increases

MT Newswires Live
·
Nov 05

Stock Track | Ultragenyx Plunges 13.68% After Selling Additional Crysvita Royalties for $400 Million

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plunges 5.98% After-Hours Following $400 Million Royalty Sale

Stock Track
·
Nov 05

Ultragenyx Reaffirms 2025 Revenue Guidance of $640 Million to $670 Million

Reuters
·
Nov 05

Ultragenyx Pharmaceutical Inc: Reaffirm 2025 Revenue Guidance

THOMSON REUTERS
·
Nov 05

Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million

Reuters
·
Nov 05

Ultragenyx Pharmaceutical Inc - Omers to Receive Additional 25% Royalty Interest on Crysvita From Jan 2028

THOMSON REUTERS
·
Nov 05

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (Burosumab) for $400 Million to Omers Life Sciences

THOMSON REUTERS
·
Nov 05

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)

TIPRANKS
·
Oct 31